Home Overview Press Room Blog Publications For Students about us
Search

Personal genomics : Displaying 21-40 of 666


Obama Precision Medicine Plan Would Create Huge U.S. Genetic Biobankby Jocelyn KaiserScience InsiderJanuary 29th, 2015The proposed precision medicine initiative would center on a huge new biobank containing medical records and genetic information for perhaps a million Americans.
‘Moonshot’ Medicine Will Let Us Downby Michael J. JoynerThe New York TimesJanuary 29th, 2015President Obama's new budget is expected to include hundreds of millions of dollars for so-called precision medicine. Unfortunately, this is unlikely to make most of us healthier.
Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testingby Andrew PollackThe New York TimesJanuary 27th, 2015The company has settled or is in the process of settling patent-infringement lawsuits it filed against other companies that now offer such testing.
Genetic Testing and Tribal Identityby Rose EvelethThe AtlanticJanuary 26th, 2015The question of genetic testing, and particularly genetic testing to determine ancestral origins, is controversial for many Native Americans.
Obama to Request Research Funding for Treatments Tailored to Patients’ DNAby Robert PearThe New York TimesJanuary 24th, 2015President Obama will seek hundreds of millions of dollars for a new initiative to develop medical treatments tailored to genetic and other characteristics of individual patients.
Privacy is dead, Harvard professors tell Davos forumAgence France PresseJanuary 22nd, 2015"We are at the dawn of the age of genetic McCarthyism," said one Harvard researcher.
UK Moratorium on Use of Genetic Tests by Insurers Extendedby Philippa BricePHG FoundationJanuary 21st, 2015The purpose of the UK moratorium is similarly to ensure that individuals are not debarred from health or life insurance as a result of genetic testing.
After Canada, UK, 23andMe Wants DNA Test Growth Abroadby Caroline Humer and Christina FarrReutersJanuary 15th, 2015The company, whose consumer-directed tests were barred by U.S. health regulators in 2013, said Western Europe is one focus for expansion.
Direct-to-Consumer Genetic Tests Should Come With a Health Warningby Jessica CussinsThe Pharmaceutical JournalJanuary 15th, 2015Genetic testing is appropriate in certain situations, but for healthy people as a way to predict disease, it is imprecise and comes with a number of risks.
Deals For Genetic Data Raise Issues of Privacy, Sharingby John Lauerman and Makiko KitamuraBloombergJanuary 14th, 2015Big Pharma is making deals to use the personal genetic data accumulated by direct-to-consumer genetic testing companies and others.
23andMe Turns Spit Into Dollars in Deal With Pfizerby Caroline ChenBloombergJanuary 12th, 2015The genetic-testing company backed by Google is sharing DNA data on about 650,000 individuals with Pfizer, the U.S.’s largest drugmaker.
23andMe’s New Formula: Patient Consent = $by Antonio RegaladoMIT Technology ReviewJanuary 6th, 2015How a consumer genetics company amassed a lucrative database of willing research participants.
Most Types of Cancer Largely Down to Bad Luck Rather Than Lifestyle or Genes The Guardian January 1st, 2015Random DNA mutations are largely responsible for two thirds of adult cancers but poor lifestyle can add to the "bad luck factor," according to a new study.
2014 in Biomedicine: Rewriting DNA, Decoding the Brain, and a GMO Paradoxby Antonio RegaladoMIT Technology ReviewDecember 30th, 2014From genetically modified foods to gene therapy, 2014 was a big year for rewriting biology.
Every Patient a Subject: When personalized medicine, genomic research, and privacy collideby Jennifer J. Kulynych and Hank GreelySlateDecember 30th, 2014Current norms permit a scientist who gets a sample of blood, tissue, or saliva to sequence and use that genome without the donor’s consent, or even without her knowledge.
Commercial DNA Testing May Cause Harm, Scientific Studies Show (If You Read Through to the Study Limitations at the End)by Cecile JanssensHuffington PostDecember 22nd, 2014After the FDA urged 23andMe to stop marketing its personal genome test in the US, the world's largest direct-to-consumer genetics company relaunched the test in Canada and the UK.
Top Biopolitical Times Posts of 2014by Jessica Cussins & Pete ShanksBiopolitical TimesDecember 18th, 2014In 2014, CGS staffers and contributors posted 107 blogs in Biopolitical Times. These are twelve of our favorites.
Geneticists Begin Tests of an Internet for DNAby Antonio RegaladoMIT Technology ReviewDecember 17th, 2014Scientists are starting to open their DNA databases online, creating a network that could pave the way for gene analysis at a new scale.
Myriad Loses Appeals Court Bid to Block Breast Cancer Testsby Susan DeckerBloomberg BusinessweekDecember 17th, 2014Myriad Genetics can’t block competitors’ DNA tests to determine risk for breast and ovarian cancer after a US appeals court said three patents on the tests never should have been issued.
Prenatal Tests: Oversold and Misunderstoodby George Estreich, Biopolitical Times guest contributorDecember 16th, 2014A scathing investigative report on the accuracy of noninvasive prenatal testing is likely to shift the terms of this important conversation.
Displaying 21-40 of 666  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760